GlassScriptPhysician profile
Emil Soorani
NPI 1053434472
$25,669.07
in general payments reported to CMS, 2019-2025
25 companies · $2,914 in 2025
The $2,914 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,102 · 2020: $5,933 · 2021: $4,172 · 2022: $653 · 2023: $7,655 · 2024: $2,239 · 2025: $2,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,428 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,850 · Travel and Lodging: $415 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,428.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,850.00 |
| Travel and Lodging | $415.07 |
| Education | $114.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,884.44 | 2021-2025 | Vraylar |
| Allergan, INC. | $7,428.84 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $945.12 | 2019-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $913.83 | 2019-2025 | Rexulti, Abilify Maintena |
| Bausch Health US, LLC | $566.52 | 2019-2025 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $555.30 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $531.76 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $524.04 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $316.59 | 2019-2025 | Rexulti |
| Alkermes, INC. | $286.30 | 2019-2025 | Lybalvi, Aristada |
| Harmony Biosciences LLC | $274.00 | 2023-2025 | Wakix |
| Idorsia Pharmaceuticals US INC | $218.57 | 2022-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $206.40 | 2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $171.08 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $139.02 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $123.80 | 2019 | |
| Neurocrine Biosciences, INC. | $112.10 | 2024-2025 | Ingrezza |
| Shire North American Group INC | $99.08 | 2019 | |
| Adlon Therapeutics L.P. | $98.35 | 2019-2020 | |
| Neos Therapeutics, LP | $94.42 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $66.41 | 2019 | |
| Avanir Pharmaceuticals, INC. | $49.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.41 | 2019 | |
| Ironshore Pharmaceuticals INC. | $21.31 | 2019 | |
| Sentynl Therapeutics, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emil Soorani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.